Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk [Clinical Sciences]

Conclusions—In patients with type 2 diabetes mellitus and high cardiovascular risk, there was no significant difference in the risk of cerebrovascular events with empagliflozin versus placebo.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01131676.

Source: Stroke - April 24, 2017 Category: Neurology Authors: Bernard Zinman, Silvio E. Inzucchi, John M. Lachin, Christoph Wanner, David Fitchett, Sven Kohler, Michaela Mattheus, Hans J. Woerle, Uli C. Broedl, Odd Erik Johansen, Gregory W. Albers, Hans Christoph Diener Tags: Cardiovascular Disease, Diabetes, Type 2, Cerebrovascular Disease/Stroke, Ischemic Stroke, Transient Ischemic Attack (TIA) Original Contributions Source Type: research